LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

22.99 -1.79

Buy Sell

Overview

Share price change

24h

Current

Min

22.68

Max

23.26

Key metrics
By Trading Economics
Income	-10M -67M
Profit margin	-7,753.425
Employees	186
EBITDA	-9.8M -73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+91.3% upside

Dividends
By Dow Jones
Next Earnings	25 Feb 2026

Market Stats
By TradingEconomics
Market Cap	143M 1.6B
Previous open	24.78
Previous close	22.99

News Sentiment

By Acuity

50%

148 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Feb 2026, 22:17 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 Feb 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Feb 2026, 23:48 UTC

Market Talk

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16 Feb 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16 Feb 2026, 23:20 UTC

Acquisitions, Mergers, Takeovers

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16 Feb 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16 Feb 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16 Feb 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16 Feb 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16 Feb 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16 Feb 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Bar Very High For Asset Deals

16 Feb 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16 Feb 2026, 22:35 UTC

Market Talk

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16 Feb 2026, 22:02 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 Feb 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16 Feb 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16 Feb 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: China's Economy Resilient; India Continues to Outperform

16 Feb 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16 Feb 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16 Feb 2026, 21:47 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16 Feb 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16 Feb 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16 Feb 2026, 21:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Interim Dividend Represents 60% Payout Ratio

16 Feb 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16 Feb 2026, 21:45 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16 Feb 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16 Feb 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16 Feb 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16 Feb 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16 Feb 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

91.3% upside

12 Months Forecast

Average 44 USD 91.3%

High 62 USD

Low 24 USD

Based on 4 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

148 / 351 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.